Complex karyotype is an inclusion criterion in 230 clinical trials for myelodysplastic syndromes, of which 164 are open and 66 are closed. Of the trials that contain Complex karyotype and myelodysplastic syndromes as inclusion criteria, 3 are early phase 1 (1 open), 84 are phase 1 (61 open), 48 are phase 1/phase 2 (35 open), 71 are phase 2 (49 open), 3 are phase 2/phase 3 (2 open), 15 are phase 3 (12 open), 1 is phase 4 (1 open), and 5 are no phase specified (3 open) [5].

Complex karyotype is an inclusion criterion in 227 clinical trials for acute myeloid leukemia, of which 150 are open and 77 are closed. Of the trials that contain Complex karyotype and acute myeloid leukemia as inclusion criteria, 3 are early phase 1 (1 open), 78 are phase 1 (52 open), 46 are phase 1/phase 2 (29 open), 80 are phase 2 (56 open), 3 are phase 2/phase 3 (2 open), 14 are phase 3 (9 open), and 3 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 69 clinical trials for acute lymphoblastic leukemia, of which 45 are open and 24 are closed. Of the trials that contain Complex karyotype and acute lymphoblastic leukemia as inclusion criteria, 2 are early phase 1 (1 open), 20 are phase 1 (10 open), 11 are phase 1/phase 2 (9 open), 31 are phase 2 (21 open), 1 is phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 58 clinical trials for chronic myelomonocytic leukemia, of which 44 are open and 14 are closed. Of the trials that contain Complex karyotype and chronic myelomonocytic leukemia as inclusion criteria, 22 are phase 1 (16 open), 16 are phase 1/phase 2 (14 open), 16 are phase 2 (12 open), and 4 are phase 3 (2 open) [5].

Complex karyotype is an inclusion criterion in 47 clinical trials for chronic myeloid leukemia, of which 33 are open and 14 are closed. Of the trials that contain Complex karyotype and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 14 are phase 1 (8 open), 9 are phase 1/phase 2 (9 open), 21 are phase 2 (15 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 32 clinical trials for multiple myeloma, of which 22 are open and 10 are closed. Of the trials that contain Complex karyotype and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (8 open), 4 are phase 1/phase 2 (3 open), 13 are phase 2 (9 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 28 clinical trials for non-hodgkin lymphoma, of which 20 are open and 8 are closed. Of the trials that contain Complex karyotype and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 8 are phase 1 (4 open), 4 are phase 1/phase 2 (4 open), and 14 are phase 2 (11 open) [5].

Complex karyotype is an inclusion criterion in 26 clinical trials for hodgkin lymphoma, of which 16 are open and 10 are closed. Of the trials that contain Complex karyotype and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 12 are phase 2 (9 open), and 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 22 clinical trials for acute biphenotypic leukemia, of which 14 are open and 8 are closed. Of the trials that contain Complex karyotype and acute biphenotypic leukemia as inclusion criteria, 6 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 12 are phase 2 (9 open), 1 is phase 3 (0 open), and 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 21 clinical trials for chronic lymphocytic leukemia, of which 15 are open and 6 are closed. Of the trials that contain Complex karyotype and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 6 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), 8 are phase 2 (7 open), and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 17 clinical trials for mantle cell lymphoma, of which 11 are open and 6 are closed. Of the trials that contain Complex karyotype and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 5 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (6 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 17 clinical trials for myeloproliferative neoplasm, of which 13 are open and 4 are closed. Of the trials that contain Complex karyotype and myeloproliferative neoplasm as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 9 are phase 2 (7 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 16 clinical trials for refractory anemia with excess blasts, of which 13 are open and 3 are closed. Of the trials that contain Complex karyotype and refractory anemia with excess blasts as inclusion criteria, 4 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), 7 are phase 2 (6 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 14 clinical trials for acute leukemia, of which 8 are open and 6 are closed. Of the trials that contain Complex karyotype and acute leukemia as inclusion criteria, 3 are phase 1 (0 open), 4 are phase 1/phase 2 (4 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 14 clinical trials for Burkitt lymphoma, of which 9 are open and 5 are closed. Of the trials that contain Complex karyotype and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (5 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 14 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 10 are open and 4 are closed. Of the trials that contain Complex karyotype and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 10 are phase 2 (8 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 13 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 13 are open and 0 are closed. Of the trials that contain Complex karyotype and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 10 are phase 2 (10 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 13 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 11 are open and 2 are closed. Of the trials that contain Complex karyotype and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 5 are phase 1 (4 open), 5 are phase 1/phase 2 (5 open), and 3 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 13 clinical trials for myelofibrosis, of which 8 are open and 5 are closed. Of the trials that contain Complex karyotype and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (3 open), and 7 are phase 2 (5 open) [5].

Complex karyotype is an inclusion criterion in 13 clinical trials for secondary acute myeloid leukemia, of which 13 are open and 0 are closed. Of the trials that contain Complex karyotype and secondary acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 7 are phase 2 (7 open) [5].

Complex karyotype is an inclusion criterion in 12 clinical trials for follicular lymphoma, of which 8 are open and 4 are closed. Of the trials that contain Complex karyotype and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open), 7 are phase 2 (5 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 12 clinical trials for marginal zone lymphoma, of which 8 are open and 4 are closed. Of the trials that contain Complex karyotype and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 7 are phase 2 (5 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 12 clinical trials for refractory anemia, of which 9 are open and 3 are closed. Of the trials that contain Complex karyotype and refractory anemia as inclusion criteria, 2 are phase 1 (0 open), 7 are phase 2 (6 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 11 clinical trials for anaplastic large cell lymphoma, of which 7 are open and 4 are closed. Of the trials that contain Complex karyotype and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 6 are phase 2 (4 open), and 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 9 clinical trials for prolymphocytic leukemia, of which 7 are open and 2 are closed. Of the trials that contain Complex karyotype and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 9 clinical trials for therapy-related acute myeloid leukemia, of which 9 are open and 0 are closed. Of the trials that contain Complex karyotype and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (7 open) [5].

Complex karyotype is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma, of which 7 are open and 1 is closed. Of the trials that contain Complex karyotype and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 4 are open and 4 are closed. Of the trials that contain Complex karyotype and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 8 clinical trials for lymphoblastic lymphoma, of which 7 are open and 1 is closed. Of the trials that contain Complex karyotype and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 8 clinical trials for lymphoma, of which 3 are open and 5 are closed. Of the trials that contain Complex karyotype and lymphoma as inclusion criteria, 3 are phase 1 (0 open), 1 is phase 1/phase 2 (0 open), 3 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 8 clinical trials for lymphoplasmacytic lymphoma, of which 5 are open and 3 are closed. Of the trials that contain Complex karyotype and lymphoplasmacytic lymphoma as inclusion criteria, 6 are phase 2 (4 open) and 2 are no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 8 clinical trials for plasma cell leukemia, of which 4 are open and 4 are closed. Of the trials that contain Complex karyotype and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open), 6 are phase 2 (3 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 7 clinical trials for mixed phenotype acute leukemia, of which 6 are open and 1 is closed. Of the trials that contain Complex karyotype and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [5].

Complex karyotype is an inclusion criterion in 7 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 3 are open and 4 are closed. Of the trials that contain Complex karyotype and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 7 clinical trials for small lymphocytic lymphoma, of which 3 are open and 4 are closed. Of the trials that contain Complex karyotype and small lymphocytic lymphoma as inclusion criteria, 4 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 7 clinical trials for therapy-related myelodysplastic syndrome, of which 7 are open and 0 are closed. Of the trials that contain Complex karyotype and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 5 clinical trials for acute undifferentiated leukemia, of which 5 are open and 0 are closed. Of the trials that contain Complex karyotype and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [5].

Complex karyotype is an inclusion criterion in 5 clinical trials for secondary myelodysplastic syndrome, of which 3 are open and 2 are closed. Of the trials that contain Complex karyotype and secondary myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 4 clinical trials for acute promyelocytic leukemia, of which 2 are open and 2 are closed. Of the trials that contain Complex karyotype and acute promyelocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 4 clinical trials for B-cell non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain Complex karyotype and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 4 clinical trials for double-hit lymphoma, of which 2 are open and 2 are closed. Of the trials that contain Complex karyotype and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 3 are phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 4 clinical trials for primary myelofibrosis, of which 2 are open and 2 are closed. Of the trials that contain Complex karyotype and primary myelofibrosis as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for acute erythroid leukemia, of which 3 are open and 0 are closed. Of the trials that contain Complex karyotype and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for acute megakaryoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain Complex karyotype and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 1 is closed. Of the trials that contain Complex karyotype and B-cell acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia-1, of which 3 are open and 0 are closed. Of the trials that contain Complex karyotype and chronic myelomonocytic leukemia-1 as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain Complex karyotype and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for natural killer cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain Complex karyotype and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for refractory anemia with ring sideroblasts, of which 3 are open and 0 are closed. Of the trials that contain Complex karyotype and refractory anemia with ring sideroblasts as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for T-cell acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain Complex karyotype and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain Complex karyotype and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for T-cell non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain Complex karyotype and T-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 3 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 2 are closed. Of the trials that contain Complex karyotype and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for acute bilineal leukemia, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and acute bilineal leukemia as inclusion criteria, 2 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for acute myeloid leukemia with myelodysplasia-related changes, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and acute myeloid leukemia with myelodysplasia-related changes as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (0 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for aggressive non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and aggressive non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for blastic plasmacytoid dendritic cell neoplasm, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and blastic plasmacytoid dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia-0, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and chronic myelomonocytic leukemia-0 as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is no phase specified (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for chronic myelomonocytic leukemia-2, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and chronic myelomonocytic leukemia-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for leukemia, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and leukemia as inclusion criteria, 2 are phase 2 (2 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain Complex karyotype and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for mature T-cell and NK-cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome with excess blasts-1, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for myelodysplastic syndrome, unclassifiable, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and myelodysplastic syndrome, unclassifiable as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for polycythemia vera, post-polycythemic myelofibrosis phase, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and polycythemia vera, post-polycythemic myelofibrosis phase as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for refractory cytopenia with multilineage dysplasia, of which 2 are open and 0 are closed. Of the trials that contain Complex karyotype and refractory cytopenia with multilineage dysplasia as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for small lymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and small lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 2 clinical trials for waldenstrom macroglobulinemia, of which 1 is open and 1 is closed. Of the trials that contain Complex karyotype and waldenstrom macroglobulinemia as inclusion criteria, 2 are phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and acute myeloid leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1 as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for adult acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and adult acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and cancer as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for core binding factor acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and core binding factor acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for desmoplastic small round cell tumor, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and desmoplastic small round cell tumor as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and Ewing sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with isolated del(5q), of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and myelodysplastic syndrome with isolated del(5q) as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for myeloma, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for NK-cell lymphoma, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and NK-cell lymphoma, unclassifiable as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and neuroblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for polycythemia vera, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and polycythemia vera as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for refractory cytopenia with unilineage dysplasia, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and refractory cytopenia with unilineage dysplasia as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for Richter syndrome, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for secondary myelofibrosis, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and secondary myelofibrosis as inclusion criteria, 1 is phase 2 (0 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and systemic mastocytosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for therapy-related myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains Complex karyotype and therapy-related myeloid neoplasm as inclusion criteria, 1 is phase 2/phase 3 (1 open) [5].

Complex karyotype is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains Complex karyotype and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].